Table 9.
Phenotypic antibiogram of clinical strain P. aeruginosa compatible with the production of AmpC enzyme.
| P. aeruginosa | Ecoculture | |
|---|---|---|
| Antibiotic | MIC | SIR * |
| Amikacin | =8.0 | S |
| Cefepime | =4.0 | I |
| Ceftazidime | =16.0 | R |
| Ceftazidime/Avibactam | =2.0 | S |
| Ceftolozane/Tazobactam | =1.0 | S |
| Ciprofloxacin | =0.125 | I |
| Colistin | =1.0 | S |
| Meropenem | =0.25 | S |
| Piperacillin/Tazobactam | =32.0 | R |
MIC = minimum inhibitory concentration; SIR = Susceptible (S), Susceptible, Iincreased Eexposure (I), and Resistant (R).* Breakpoint sec. Clinical breakpoints (v 13.1) [44].Comment: tThe antibiogram shows a resistance profile to ceftazidime and piperacillin/tazobactam. Instead, cCefepime is still intermediate. Meropenem and new BL/BLIs are susceptible. This phenotype is compatible with the AmpC P. aeruginosa strain.